PDUFA Acronym War Begins: Could Reauthorization Be Called Patient-UFA?
Executive Summary
For first time ever, the administration that negotiated a user fee agreement won’t be shepherding its reauthorization through Congress.
You may also be interested in...
PDUFA VI: Industry Ready For 'Hard Sell' To Keep Agreement Intact
Biopharma industry is preparing for the unwelcome possibility that the new Congress and Trump Administration will seek to revisit provisions in the negotiated agreement for the US FDA user fee program's reauthorization.
21st Century Cures Revisions Tell FDA To Highlight ‘Patient Experience Data’
Lame-duck passage is goal of changes to reform legislation, which now includes highly targeted funding for FDA.
21st Century Cures Revisions Tell FDA To Highlight ‘Patient Experience Data’
Lame-duck passage is goal of changes to reform legislation, which now includes highly targeted funding for FDA.